BCDA vs MCRB vs ANIK vs MDXG vs NVCR

For growth investors, MiMedx Group, Inc.

(MDXG) is the stronger pick with 20. 0% revenue growth year-over-year, versus -87. 8% for BioCardia, Inc. (BCDA). MiMedx Group, Inc. (MDXG) offers the better valuation at 11. 5x trailing P/E (295. 2x forward), making it the more compelling value choice. Analysts rate Seres Therapeutics, Inc. (MCRB) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, MiMedx Group, Inc.

(MDXG) is the cheapest at 11. 5x versus Seres Therapeutics, Inc. at 12. 1x.

Over the past 5 years, MiMedx Group, Inc.

(MDXG) delivered a total return of -62. 9%, compared to -99. 3% for BioCardia, Inc. (BCDA). Over 10 years, the gap is even starker: NVCR returned +30. 3% versus BCDA's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioCardia, Inc.

(BCDA) is the lower-risk stock at 1. 14β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 93% more volatile than BCDA relative to the S&P 500. On balance sheet safety, MiMedx Group, Inc. (MDXG) carries a lower debt/equity ratio of 9% versus 188% for Seres Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), MiMedx Group, Inc.

(MDXG) is pulling ahead at 20. 0% versus -87. 8% for BioCardia, Inc. (BCDA). On earnings-per-share growth, the picture is similar: Seres Therapeutics, Inc. grew EPS 103. 4% year-over-year, compared to 14. 3% for MiMedx Group, Inc.. Over a 3-year CAGR, MDXG leads at 16. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Seres Therapeutics, Inc.

(MCRB) is the more profitable company, earning 721. 9% net margin versus -137. 0% for BioCardia, Inc. — meaning it keeps 721. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDXG leads at 15. 3% versus -137. 9% for BCDA. At the gross margin level — before operating expenses — MDXG leads at 82. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for MDXG: 171.

0% to $10. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Anika Therapeutics, Inc.

(ANIK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 14)). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ANIK: -65. 9%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: BCDA is a small-cap quality compounder stock; MCRB is a small-cap deep-value stock; ANIK is a small-cap quality compounder stock; MDXG is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.